Uremic Leontiasis Ossea due to Resistant Secondary Hyperparathyroidism
AACE Clinical Case Reports · 2025-01 · 11 (1) · 5-9
DOI: 10.1016/j.aace.2024.09.001 ↗Kurz gefasst
Fallbericht in der Zeitschrift AACE Clinical Case Reports, 2025-01. Verfasst von Kubra Tuna und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Metabolism, University of Florida College of Medicine, Gainesville, Florida. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background/Objective: Severe progressive overgrowth of the facial bones known as uremic leontiasis ossea (ULO) is a rare complication of resistant hyperparathyroidism in end-stage renal disease (ESRD). The objective of this report is to describe the presentation and treatment of ULO. Case Report: A 48-year-old woman with a history of hypertension, coronary artery disease, and ESRD on hemodialysis presented with severe secondary hyperparathyroidism and calciphylaxis. She had significant changes to her face in the last 3 months leading to oropharyngeal dysphagia and difficulty articulating. Physical examination revealed bony overgrowth in her upper jaw and hard palate, widely spaced teeth, and calcinosis cutis. Her parathyroid hormone (PTH), calcium, and phosphorus levels were 5066 pg/mL (normal range, 12-88 pg/mL); 10.0 mg/dL (8.4-10.2 mg/dL); and 5.4 mg/dL (2.7-4.5 mg/dL); respectively. Using a multidisciplinary approach, she successfully underwent a 3.5-gland parathyroidectomy (immediate postoperative PTH level, 600 pg/mL). She was discharged without complication. Pathology showed hypercellular parathyroid glands with reactive changes.
Discussion
ULO, the most severe form of renal osteodystrophy, results in hypertrophy of the craniofacial skeleton. It carries the risk of significant comorbidities due to cranial nerve compression, respiratory compromise, dysarthria, and dysphagia.
Conclusion
With prolonged, uncontrolled PTH stimulation in ESRD, significant facial disfiguration with disabilities can occur. It is of utmost importance to adhere to guideline-specified PTH targets in persons with ESRD to prevent patient harm from permanent physical deformities.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Metabolism, University of Florida College of Medicine, Gainesville, Florida.
- Division of Nephrology, University of Florida College of Medicine, Gainesville, Florida.
- Department of Otolaryngology, University of Florida College of Medicine, Gainesville, Florida.
Zitieren
APA
Tuna, K., Ilkun, O., Dziegielewski, P. T., & Sharma, A. (2025). Uremic Leontiasis Ossea due to Resistant Secondary Hyperparathyroidism. AACE Clinical Case Reports, 11(1), 5-9. https://doi.org/10.1016/j.aace.2024.09.001
Vancouver
Tuna K, Ilkun O, Dziegielewski PT, Sharma A. Uremic Leontiasis Ossea due to Resistant Secondary Hyperparathyroidism. AACE Clinical Case Reports. 2025;11(1):5-9. doi:10.1016/j.aace.2024.09.001
BibTeX
@article{Tuna2025,
author = {Tuna, Kubra and Ilkun, Olesya and Dziegielewski, Peter T and Sharma, Anu},
title = {Uremic Leontiasis Ossea due to Resistant Secondary Hyperparathyroidism},
journal = {AACE Clinical Case Reports},
year = {2025},
volume = {11},
number = {1},
pages = {5--9},
doi = {10.1016/j.aace.2024.09.001}
}
EUVIMED